Dr. Nathan Price is Chief Scientific Officer of Thorne HealthTech (NASDAQ: THRN). Previously he was CEO of Onegevity, an AI health intelligence company that merged with Thorne prior to its IPO in 2021. In 2019, he was named as one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine, and in 2021 he was appointed to the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine.
Dr. Price spent much of his earlier career as Professor and Associate Director of the Institute for Systems Biology (now on leave), co-director with biotechnology pioneer Lee Hood of the Hood-Price Lab for Systems Biomedicine, and is Affiliate Faculty at the University of Washington in Bioengineering and Computer Science & Engineering. Prior to that he was an Assistant Professor at the University of Illinois, Urbana-Champaign in Chemical & Biomolecular Engineering and at the Institute for Genomic Biology. He is a Camille Dreyfus Teacher-Scholar, received the 2016 Grace A. Goldsmith award for his work pioneering ‘scientific wellness’, was a co-founder of Arivale, and received a Healthy Longevity Catalyst Award from the National Academy of Medicine in 2020. He has co-authored more than 200 peer-reviewed scientific publications and given over 200 talks and keynotes. He also served as Chair of the NIH Study Section on Modeling and Analysis of Biological Systems.
Dr. Price has won numerous awards for his work, including a Howard Temin Pathway to Independence Award from the National Institutes of Health, a National Science Foundation CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, “Tomorrow’s PIs” from Genome Technology, a Camille Dreyfus Teacher-Scholar award, the Grace A. Goldsmith Award from the American College of Nutrition (given to 1 researcher each year under the age of 50, for his work pioneering "scientific wellness"), and is a National Academy of Medicine ELHM Scholar. In 2020, he was elected a fellow of the American Institute for Medical and Biological Engineering and received a Healthy Longevity Catalyst Award from the National Academy of Medicine for work on the microbiome and aging. He was also a finalist for the EY Entrepreneur of the Year for NY in 2021.
Dr. Price has served on numerous advisory boards including for Roche (Personalized Healthcare Division), Providence St. Joseph Health, Sera Prognostics, Navican, Basepaws, Trelys, the Novo Nordisk Foundation Center for Biosustainability and many others. Dr. Price served on the NAM committee to review omics-based tests for clinical trials. He also served on the Board of Trustees of the Health and Environmental Sciences Institute (HESI) and the American Cancer Society (ACS) Board of Advisors (WA).